Anxiety Disorders Completed Phase 3 Trials for Venlafaxine (DB00285)

Also known as: Anxiety Disorder / Anxiety NOS

IndicationStatusPhase
DBCOND0027904 (Anxiety Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00122850A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety DisorderTreatment
NCT00122837A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety DisorderTreatment